Volume 18, Issue 1 (Jan-Feb 2024)                   mljgoums 2024, 18(1): 34-37 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Alhashem R, Hosseini S S. Epidemiological profile and fluconazole susceptibility of patients with vulvovaginal candidiasis in northeast Iran. mljgoums 2024; 18 (1) :34-37
URL: http://mlj.goums.ac.ir/article-1-1700-en.html
1- Laboratory Sciences Research Center, Golestan University of Medical sciences, Gorgan, Iran.
2- Laboratory Sciences Research Center, Golestan University of Medical sciences, Gorgan, Iran. , hoseini.sedigheh@gmail.com
Abstract:   (326 Views)
Background: Vulvovaginal candidiasis (VVC) remains one of the most common infections of the female genital tract. This local study was conducted to identify the spectrum of Candida species associated with VVC and recurrent vulvovaginal candidiasis (RVVC) using different phenotypic and genotypic methods and assess their fluconazole susceptibility.
Methods: High vaginal swabs were collected from 576 patients with VVC. Swabs were subjected to KOH 10% and cultured on Sabouraud dextrose agar. The species identification of Candida isolates was made using phenotypic methods, including the germ tube test, corn meal agar (CMA), CHROMagar Candida, and PCR-RFLP as the best genotypic methods for confirmation of Candida species in vulvovaginal candidiasis. Fluconazole susceptibility testing was performed using the disk diffusion method.
Results: The data were analyzed using the chi-square test. The prevalence of candidiasis was 61%. The socio-demographic profile corresponded to a woman aged 29.14 ± 4.8 years on average, pregnant (77%), diabetic (19%), with hypertension (10%), recurrent (9%), a history of fluconazole use (4%), and under 30 years of age (73%).
Vaginal swab cultures yielded Candida growth in 352 cases (61%). Candida albicans was the predominant isolated species (78%), while the most common non-albicans species were C. glabrata (14.7%), C. parapsilosis (4.2%), C. tropicalis (2.8%), and C. krusei (0.56%). Isolates of C. glabrata and C. krusei exhibited the highest rate of DDS resistance among all isolates tested.
Conclusion: C. albicans was the most common species. Careful periodical surveillance is needed to identify any changes in the susceptibility patterns to fluconazole with the increased use of this antifungal agent in Sayad Shirazi tertiary care hospital, Iran.

Full-Text [PDF 521 kb]   (83 Downloads) |   |   Full-Text (HTML)  (33 Views)  
Research Article: Research Article | Subject: Mycology
Received: 2023/08/14 | Accepted: 2023/10/2 | Published: 2024/02/29 | ePublished: 2024/02/29

1. Dadar M, Tiwari R, Karthik K, Chakraborty S, Shahali Y, Dhama K. Candida albicans - Biology, molecular characterization, pathogenicity, and advances in diagnosis and control - An update. Microb Pathog. 2018;117:128-38. [View at Publisher] [DOI] [PMID] [Google Scholar]
2. Scharmann U , Kirchhoff L , Saout Chapot VL , Dziobaka J , Verhasselt HL , Stauf R , et al. Comparison of four commercially available chromogenic media to identify Candida albicans and other medically relevant Candida species. Mycoses. 2020;63(8):823-31. [View at Publisher] [DOI] [PMID] [Google Scholar]
3. Sikora M, Dabkowska M, Swoboda-Kopec E, Jarzynka, Netsvyetayeva I, Jaworska-Zaremba M, et al. Differences in proteolytic activity and gene gene profiles of fungal strains isolated from the total parenteral nutrition patients. Folia Microbiol (Praha). 2011;56(2):143-8. [View at Publisher] [DOI] [PMID] [Google Scholar]
4. Hosseini SS, Yadegari MH, Rajabibazl M, Ghaemi EA. Inhibitory effects of carvacrol on the expression of secreted aspartyl proteinases 1-3 in fluconazole- resistant Candida albicans isolates. Iran J Microbiol. 2016;8(6):401-9. [View at Publisher] [PMID] [Google Scholar]
5. Brandolt TM, Klafke GB, Gonçalves CV, Bitencourt LR, Barral de Martinez AM, Mendes JF, et al. Prevalence of Candida spp. in cervical-vaginal samples and the in vitro susceptibility of isolates. Braz J Microbiol. 2017;48(1):145-50. [View at Publisher] [DOI] [PMID] [Google Scholar]
6. Benedict K, Singleton AL, Jackson BR, Molinari NAM. Survey of incidence, lifetime prevalence, and treatment of selfreported vulvovaginal candidiasis, United States, 2020. BMC Womens Health. 2022;22(1):147. [View at Publisher] [DOI] [PMID] [Google Scholar]
7. Mushi MF, Olum R, Bongomin F. Prevalence, antifungal susceptibility and etiology of vulvovaginal candidiasis in sub-Saharan Africa: A systematic review with meta-analysis and meta-regression. Med Mycol. 2022;60(7):myac037. [View at Publisher] [DOI] [PMID] [Google Scholar]
8. Boros E, Pfliegler WP, Kovács R, Jakab Á, Majoros L, Barta Z, et al. Candida albicans isolates from a single hospital show low phenotypical specialization. J Basic Microbiol. 2017;57(11):910-21. [View at Publisher] [DOI] [PMID] [Google Scholar]
9. Wypij M, Czarnecka J, Dahm H, Rai M. Silver nanoparticles from Pilimelia columellifera subsp. Pallida SL19 strain demonstrated antifungal activity against fungi causing superficial mycoses. J Basic Microbiol. 2017;57(9):793-800. [View at Publisher] [DOI] [PMID] [Google Scholar]
10. Yao D, Chen J, Chen W, Li Z, Hu X. Mechanisms of azole resistance in clinical isolates of Candida glabrata from two hospitals in China. Infect Drug Resist. 2019;12:771-81. [View at Publisher] [DOI] [PMID] [Google Scholar]
11. Gu W, Guo D, Zhang L, Xu D, Sun S. The Synergistic Effect of Azoles and Fluoxetine against Resistant Candida albicans Strains Is Attributed to Attenuating Fungal Virulence. Antimicrob Agents Chemother. 2016;60(10):6179-88. [View at Publisher] [DOI] [PMID] [Google Scholar]
12. Todd JC, Sanford AH, Davidsohn I, Henry JB. Clinical diagnosis and management by laboratory methods. 16th ed. Philadelphia:Saunders;1979. [View at Publisher] [Google Scholar]
13. Bradfield Strydom M, Walpola RL, McMillan S, Khan S, Ware RS, Tiralongo E. Lived experience of medical management in recurrent vulvovaginal candidiasis: A qualitative study of an uncertain journey. BMC Womens Health. 2022;22(1):384. [View at Publisher] [DOI] [PMID] [Google Scholar]
14. Sustr V, Foessleitner P, Kiss H, Farr A. Vulvovaginal Candidosis: Current Concepts, Challenges and Perspectives. J Fungi. 2020;6(4):267. [View at Publisher] [DOI] [PMID] [Google Scholar]
15. Mucci MJ, Cuestas ML, Landanburu MF, Mujica MT. Prevalence of Candida albicans, Candida dubliniensis and Candida africana in pregnant women suffering from vulvovaginal candidiasis in Argentina. Rev Iberoam Micol. 2019;34(2):72-6. [View at Publisher] [DOI] [PMID] [Google Scholar]
16. Willems HME, Ahmed SS, Liu J, Xu Z, Peters BM. Vulvovaginal Candidiasis: A Current Understanding and Burning Questions. J Fungi. 2020;6(1):27. [View at Publisher] [DOI] [PMID] [Google Scholar]
17. Intra J, Sala MR, Brambilla P, Carcione D, Leoni V. Prevalence and species distribution of microorganisms isolated among non-pregnant women affected by vulvovaginal candidiasis: A retrospective study over a 20 year-period. J Mycol Med. 2022;32(3):101278. [View at Publisher] [DOI] [PMID] [Google Scholar]
18. Maraki S, Mavromanolaki VE, Stafylaki D, Nioti E, Hamilos G, Kasimati A. Epidemiology and antifungal susceptibility patterns of Candida isolates from Greek women with vulvovaginal candidiasis. Mycoses. 2019;62(8):692-7. [View at Publisher] [DOI] [PMID] [Google Scholar]
19. Musthafa KS, Hmoteh J, Thamjarungwong B, Voravuthikunchai SP. Antifungal potential of eugenyl acetate against clinical isolates of Candida species. Microb Pathog. 2016;99:19-29. [View at Publisher] [DOI] [PMID] [Google Scholar]
20. Donders G, Sziller IO, Paavonen J, Hay P, de Seta F, Bohbot JM, et al. Management of recurrent vulvovaginal candidosis: Narrative review of the literature and European expert panel opinion. Front Cell Infect Microbiol. 2022;12:934353. [View at Publisher] [DOI] [PMID] [Google Scholar]
21. Jaqueti Aroca J, Ramiro Martínez P, Molina Esteban LM, Fernández González AM, García-Arata I, Prieto Menchero S. Epidemiology and etiology of vulvovaginal candidiasis in Spanish and immigrants' women in Fuenlabrada (Madrid). Rev Esp Quimioter. 2020;33(3):187-92. [View at Publisher] [DOI] [PMID] [Google Scholar]
22. Cooke G, Watson C, Deckx L, Pirotta M, Smith J, van Driel ML. Treatment for recurrent vulvovaginal candidiasis (thrush). Cochrane Database Syst Rev. 2022;1(1):CD009151. [View at Publisher] [DOI] [PMID] [Google Scholar]
23. Sobel JD, Sobel R. Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species. Expert Opin. Pharmacother. 2018;19(9):971-7. [View at Publisher] [DOI] [PMID] [Google Scholar]

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2007 All Rights Reserved | Medical Laboratory Journal

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.